Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2016 - 2020)

Agios Pharmaceuticals' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $571000.0 for Q1 2020.

  • For Q1 2020, Non-Current Deffered Revenue changed N/A year-over-year to $571000.0; the TTM value through Mar 2020 reached $571000.0, changed N/A, while the annual FY2019 figure was $50.6 million, 15.43% down from the prior year.
  • Non-Current Deffered Revenue reached $571000.0 in Q1 2020 per AGIO's latest filing, down from $50.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $173.9 million in Q3 2016 to a low of $571000.0 in Q1 2020.
  • Average Non-Current Deffered Revenue over 5 years is $55.5 million, with a median of $50.2 million recorded in 2019.
  • The largest YoY upside for Non-Current Deffered Revenue was 7626.83% in 2017 against a maximum downside of 91.33% in 2017.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $17.8 million in 2016, then surged by 607.8% to $125.8 million in 2017, then tumbled by 52.46% to $59.8 million in 2018, then decreased by 15.43% to $50.6 million in 2019, then plummeted by 98.87% to $571000.0 in 2020.
  • Per Business Quant, the three most recent readings for AGIO's Non-Current Deffered Revenue are $571000.0 (Q1 2020), $50.6 million (Q4 2019), and $49.8 million (Q3 2019).